Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), retaining the price target of A$35.00.
Tara Bancroft’s rating is based on Telix Pharmaceuticals Ltd.’s strong financial performance and promising growth prospects. The company reported a significant increase in revenue for the first quarter, with a 31% quarter-over-quarter and 62% year-over-year growth, indicating robust business momentum. This strong performance suggests that Telix is on track to surpass the consensus revenue estimates for the first half of the year.
Tara Bancroft also highlights the potential for additional revenue streams from new products and markets. The company’s revenue guidance for 2025 does not yet include contributions from several new products and international markets, which are expected to start generating revenue soon. The positive regulatory developments and approvals in various countries further bolster the company’s growth outlook, leading to an increased price target and a Buy rating for the stock.
According to TipRanks, Bancroft is an analyst with an average return of -18.2% and a 22.22% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Telix Pharmaceuticals Ltd., and Vaxcyte.
In another report released on April 8, UBS also maintained a Buy rating on the stock with a A$36.00 price target.